Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors ; volume:13 ; number:1 ; day:28 ; month:10 ; year:2022 ; pages:1-10 ; date:12.2022
Nature Communications ; 13, Heft 1 (28.10.2022), 1-10, 12.2022

Creator: Beroza, Paul
Crawford, James J.
Ganichkin, Oleg
Gendelev, Leo
Harris, Seth F.
Klein, Raphael
Miu, Anh
Steinbacher, Stefan
Klingler, Franca-Maria
Lemmen, Christian

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-022-33981-8

URN: urn:nbn:de:101:1-2023011321185510431827

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Beroza, Paul
Crawford, James J.
Ganichkin, Oleg
Gendelev, Leo
Harris, Seth F.
Klein, Raphael
Miu, Anh
Steinbacher, Stefan
Klingler, Franca-Maria
Lemmen, Christian
SpringerLink (Online service)

Other Objects (12)

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Chemical space docking enables large-scale structure-based virtual screening to discover ROCK1 kinase inhibitors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Glide XP fragment docking and structurebased pharmacophores

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands

Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening

Decomposing compounds enables reconstruction of interaction fingerprints for structure‑based drug screening

Large-scale reverse docking profiles and their applications

Evaluation of the performance of 3D virtual screening programs: docking vs. structure-based pharmacophore

Structure-based design, docking and binding free energy calculations of A366 derivatives as spindlin1 inhibitors

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

Structure-based redesign of docking domain interactions modulates the product spectrum of a rhabdopeptide-synthesizing NRPS

In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis

Related objects

Reset password